Product Description
SM-88 (racemetyrosine) is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. Oral SM-88 has demonstrated meaningful clinical benefit and well tolerated safety profile, in metastatic cancer patients across 15 different types of solid tumors and hematologic cancers. (Sourced from: https://tymeinc.com/our-science/sm-88-overview/default.aspx)
Mechanisms of Action: Tyrosine hydroxylase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Pancreatic Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Syros
Company Location: CAMBRIDGE MA 02140
Company CEO: Nancy Simonian
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Peripheral Neuroectodermal Tumors, Primitive|Primitive Neuroectodermal Tumors|Sarcoma, Ewing
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HopES | P2 |
Active, not recruiting |
Primitive Neuroectodermal Tumors|Sarcoma, Ewing|Peripheral Neuroectodermal Tumors, Primitive |
2024-12-19 |